Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
NCT01029886 on ClinicalTrials.gov · last registry update 2015-04-09
An unusually large phase 3: 912 participants, more than double the 424 typical for the stage. The sponsor logged completion for January 2011. Primary outcome, as filed: Change in HbA1c From Baseline to Week 26. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- AstraZeneca
- Sponsor type
- Industry
- Enrollment
- 912
- Started
- 2010-01
- Primary completion
- 2011-01 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change in HbA1c From Baseline to Week 26
Conditions studied
Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.